Side-by-side · Research reference
KPVvsSermorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft13/39 cited
BPhase 3Reviewed14/43 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
Sermorelin
GHRH 1-29 fragment · Short-acting
SQ · Pre-sleep · 1×/day
01Mechanism of Action
Parameter
KPV
Sermorelin
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pituitary GHRH receptorWalker 1994
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
No melanocortin receptor binding
Yes — short pulse preserves feedback
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
Sermorelin
Frequency
Daily or 2–3× per week
Once daily, pre-sleep
Lower / starter dose
100 mcg / day
100 mcg per dose
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Duration
4–8 weeks per cycle
8–12 weeks per cycle
Reconstitution
Bacteriostatic water (SQ form)
Bacteriostatic water
Timing
No specific time; often taken with / before meals (oral)
Pre-sleep, fasted preferred
Half-life
Hours (estimated; rapid tissue uptake)
~12 min (plasma)Molteno 2013
Shorter than tesamorelin (~26 min) — simpler GHRH analogue.
04Side Effects & Safety
Parameter
KPV
Sermorelin
Injection site reaction
Mild irritation
Mild erythema, transient pain
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
Avoid
Flushing / headache
—
Common transient effect
IGF-1 elevation
—
Modest at standard doses
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Glucose handling
—
Generally neutral
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
Sermorelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
Sermorelin
- ·Untreated diabetes
05Administration Protocol
Parameter
KPV
Sermorelin
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Morning preferred; oral form taken with / before meals.
Pre-sleep, fasted.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G insulin syringe (SQ form).
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
Sermorelin
+ Ipamorelin
StrongSermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.
- Sermorelin
- 200–300 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition